Press Releases

NeoTX Announces Clinical Trial Poster Presentation at AACR 2023 Annual Meeting

REHOVOT, ISRAEL – April 11, 2023

NeoTX Therapeutics (NeoTX), a clinical-stage immuno-oncology drug development company, announced abstract acceptance at the American Association for Cancer Research (AACR) 2023 Annual Meeting being held April 14-19, 2023, at the Orange County Convention Center, Orlando, Florida. The poster will present the results of safety and preliminary activity in a phase 1b dose escalation trial of naptumomab estafenatox (NAP) combined with durvalumab in patients with advanced or metastatic solid tumors.

Details on the presentation are as follows:

  • Abstract Title: Safety and Preliminary Activity of Naptumomab Estafenatox (NAP) and Durvalumab in Patients with Advanced or Metastatic Solid Tumors: Interim results from a Phase 1b Trial
  • Abstract Number: CT205
  • Location:Poster Section 46
  • Poster Board Number:18
  • Session Title: Phase I Clinical Trials
  • Session Date & Time: Tuesday Apr 18, 2023, 9:00 AM – 12:30 PM


About NeoTX

NeoTX is a clinical-stage immuno-oncology company which is developing targeted anticancer immunotherapies utilizing its proprietary Tumor Targeted Superantigen (TTS) platform. TTS binds a genetically engineered bacterial determinant to the tumor surface while simultaneously activating and expanding tumor specific immune cells that are then redirected from the periphery to the tumor to mount an immune response. The company’s lead TTS molecule, naptumomab estafenatox (NAP) is currently in clinical development for advanced solid tumors. For more information, please visit

Investor and Media Contact:
Robert Harow, CFOO
NeoTX Therapeutics Ltd
+1 609-718-2305 x204
+972 3 912 5853 x204